The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Tissue-Agnostic Cancer Treatment: Targeting Molecular Alterations Across Tumor Types

Modern oncology paradigm targeting specific molecular alterations regardless of tumor histology with FDA-approved tissue-agnostic therapies

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Tissue-Agnostic Cancer Treatment: Targeting Molecular Alterations Across Tumor Types?

Tissue-agnostic treatment selects therapy based on molecular alterations rather than tumor histology.

FDA-approved tissue-agnostic therapies span MSI-H, NTRK fusion, RET fusion, BRAF V600E, TMB-H, FGFR.

Comprehensive molecular profiling through next-generation sequencing identifies targetable alterations.

Approach has dramatically improved outcomes for patients with rare alterations.

Multidisciplinary molecular tumor boards optimize treatment selection across diverse cancers.

Symptoms

Cancer-specific symptoms vary widely depending on primary tumor site and metastatic pattern.
Targeted therapy and immunotherapy adverse effects depend on specific agent.
Immune-related adverse events with checkpoint inhibitors require monitoring and management.
Hyperprogression in subset of patients on immunotherapy requires recognition and alternative therapy.
Drug-specific toxicities including dermatologic, gastrointestinal, hepatic, endocrine require monitoring.

Risk Factors

Lynch syndrome with germline mismatch repair gene mutations causes many MSI-H cancers.
Tobacco-related cancers often have higher tumor mutational burden suitable for immunotherapy.
NTRK fusions occur rarely (less than 1%) but are highly enriched in some rare tumor types.
RET fusions occur in NSCLC and thyroid cancers among other tumors.
FGFR alterations occur in cholangiocarcinoma, urothelial cancer and other tumors.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Advanced or metastatic cancer warrants comprehensive molecular profiling for tissue-agnostic options.
  • Molecular tumor board referral with experienced multidisciplinary teams optimizes treatment.
  • Severe immune-related adverse events or targeted therapy toxicities require urgent evaluation.
  • Disease progression on initial therapy may warrant rebiopsy and updated molecular profiling.
  • Clinical trial consideration for novel tissue-agnostic agents particularly in academic centers.

Treatment Methods

01
Pembrolizumab or dostarlimab for MSI-H or dMMR cancers regardless of histology.
02
Larotrectinib or entrectinib for NTRK fusion-positive cancers with high response rates.
03
Selpercatinib or pralsetinib for RET fusion-positive cancers across tumor types.
04
Dabrafenib-trametinib for BRAF V600E-mutant solid tumors after initial standard therapy.
05
Comprehensive multidisciplinary care with molecular oncology, comprehensive next-generation sequencing tumor profiling, molecular tumor board review for rare alterations, treatment selection based on level of evidence and prior therapies, monitoring for response and resistance, sequential therapy planning at progression, side effect monitoring and management, clinical trial enrollment for novel agents, considering rare tumor types where tissue-agnostic therapies dramatically improve outcomes, fertility preservation considerations, supportive care, and survivorship care addressing long-term effects of targeted therapy and immunotherapy provides optimal outcomes for patients with cancer harboring targetable molecular alterations.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.